vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Atlanta Braves Holdings, Inc. (BATRA). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $72.0M, roughly 1.9× Atlanta Braves Holdings, Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -56.1%, a 91.6% gap on every dollar of revenue. On growth, Atlanta Braves Holdings, Inc. posted the faster year-over-year revenue change (52.5% vs 18.4%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -49.5%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Atlanta Braves Holdings, Inc. is a sports and entertainment holding company that owns and operates the Atlanta Braves MLB franchise. It also manages adjacent mixed-use real estate, live events, merchandise sales, and media operations, serving fans across the U.S. Southeast and global baseball audiences.
ADMA vs BATRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $72.0M |
| Net Profit | $49.4M | $-40.4M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | — |
| Net Margin | 35.5% | -56.1% |
| Revenue YoY | 18.4% | 52.5% |
| Net Profit YoY | -55.9% | 2.3% |
| EPS (diluted) | $0.20 | $-0.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $72.0M | ||
| Q4 25 | $139.2M | $61.3M | ||
| Q3 25 | $134.2M | $311.5M | ||
| Q2 25 | $122.0M | $312.4M | ||
| Q1 25 | $114.8M | $47.2M | ||
| Q4 24 | $117.5M | $52.1M | ||
| Q3 24 | $119.8M | $290.7M | ||
| Q2 24 | $107.2M | $282.9M |
| Q1 26 | — | $-40.4M | ||
| Q4 25 | $49.4M | $-41.4M | ||
| Q3 25 | $36.4M | $30.0M | ||
| Q2 25 | $34.2M | $29.5M | ||
| Q1 25 | $26.9M | $-41.4M | ||
| Q4 24 | $111.9M | $-19.1M | ||
| Q3 24 | $35.9M | $10.0M | ||
| Q2 24 | $32.1M | $29.1M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 45.1% | -81.2% | ||
| Q3 25 | 38.0% | 12.5% | ||
| Q2 25 | 35.1% | 13.4% | ||
| Q1 25 | 30.4% | -94.2% | ||
| Q4 24 | 32.6% | -35.8% | ||
| Q3 24 | 33.1% | 2.2% | ||
| Q2 24 | 36.6% | 8.8% |
| Q1 26 | — | -56.1% | ||
| Q4 25 | 35.5% | -67.6% | ||
| Q3 25 | 27.1% | 9.6% | ||
| Q2 25 | 28.1% | 9.4% | ||
| Q1 25 | 23.4% | -87.7% | ||
| Q4 24 | 95.2% | -36.7% | ||
| Q3 24 | 30.0% | 3.4% | ||
| Q2 24 | 29.9% | 10.3% |
| Q1 26 | — | $-0.63 | ||
| Q4 25 | $0.20 | $-0.64 | ||
| Q3 25 | $0.15 | $0.47 | ||
| Q2 25 | $0.14 | $0.46 | ||
| Q1 25 | $0.11 | $-0.66 | ||
| Q4 24 | $0.45 | $-0.29 | ||
| Q3 24 | $0.15 | $0.16 | ||
| Q2 24 | $0.13 | $0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $135.2M |
| Total DebtLower is stronger | $72.1M | $709.2M |
| Stockholders' EquityBook value | $477.3M | $519.0M |
| Total Assets | $624.2M | $1.7B |
| Debt / EquityLower = less leverage | 0.15× | 1.37× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $135.2M | ||
| Q4 25 | $87.6M | $99.9M | ||
| Q3 25 | $61.4M | $82.2M | ||
| Q2 25 | $90.3M | $96.2M | ||
| Q1 25 | $71.6M | $244.7M | ||
| Q4 24 | $103.1M | $110.1M | ||
| Q3 24 | $86.7M | $100.9M | ||
| Q2 24 | $88.2M | $121.2M |
| Q1 26 | — | $709.2M | ||
| Q4 25 | $72.1M | $738.6M | ||
| Q3 25 | $72.4M | $759.9M | ||
| Q2 25 | — | $703.1M | ||
| Q1 25 | — | $699.5M | ||
| Q4 24 | $72.3M | $617.1M | ||
| Q3 24 | — | $640.1M | ||
| Q2 24 | — | $600.0M |
| Q1 26 | — | $519.0M | ||
| Q4 25 | $477.3M | $526.0M | ||
| Q3 25 | $431.2M | $560.3M | ||
| Q2 25 | $398.3M | $522.8M | ||
| Q1 25 | $373.4M | $486.1M | ||
| Q4 24 | $349.0M | $524.2M | ||
| Q3 24 | $231.9M | $530.4M | ||
| Q2 24 | $188.3M | $512.7M |
| Q1 26 | — | $1.7B | ||
| Q4 25 | $624.2M | $1.6B | ||
| Q3 25 | $568.7M | $1.7B | ||
| Q2 25 | $558.4M | $1.7B | ||
| Q1 25 | $510.6M | $1.7B | ||
| Q4 24 | $488.7M | $1.5B | ||
| Q3 24 | $390.6M | $1.6B | ||
| Q2 24 | $376.4M | $1.6B |
| Q1 26 | — | 1.37× | ||
| Q4 25 | 0.15× | 1.40× | ||
| Q3 25 | 0.17× | 1.36× | ||
| Q2 25 | — | 1.34× | ||
| Q1 25 | — | 1.44× | ||
| Q4 24 | 0.21× | 1.18× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.17× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $26.4M | ||
| Q3 25 | $13.3M | $-88.8M | ||
| Q2 25 | $21.1M | $-8.1M | ||
| Q1 25 | $-19.7M | $95.8M | ||
| Q4 24 | $50.2M | $28.9M | ||
| Q3 24 | $25.0M | $-69.0M | ||
| Q2 24 | $45.6M | $-34.3M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | $-82.3M | ||
| Q1 25 | $-24.4M | $76.3M | ||
| Q4 24 | $47.5M | $16.8M | ||
| Q3 24 | $24.0M | $-85.5M | ||
| Q2 24 | $43.6M | $-64.1M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | -26.3% | ||
| Q1 25 | -21.2% | 161.5% | ||
| Q4 24 | 40.4% | 32.3% | ||
| Q3 24 | 20.0% | -29.4% | ||
| Q2 24 | 40.7% | -22.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 0.0% | ||
| Q3 25 | 10.7% | 0.0% | ||
| Q2 25 | 2.0% | 23.7% | ||
| Q1 25 | 4.1% | 41.3% | ||
| Q4 24 | 2.3% | 23.2% | ||
| Q3 24 | 0.9% | 5.7% | ||
| Q2 24 | 1.9% | 10.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | -2.96× | ||
| Q2 25 | 0.62× | -0.28× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | -6.89× | ||
| Q2 24 | 1.42× | -1.18× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
BATRA
| Baseball revenue | $45.7M | 64% |
| Baseball event | $23.7M | 33% |
| Broadcasting | $2.5M | 3% |
